Pyxis Oncology, Inc. PYXS 深 沪
已收盘 08-01 16:00:00 美东时间
1.10
-0.020
-1.79%
华盛通- 最 高1.13
- 今 开1.10
- 成交量 16.52万股
- 最 低 1.085
- 昨 收 1.12
- 总市值 6814.25万
- 52周最高 5.3899
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.8332
- 委 比 -82.60%
- 总股本 6194.77万
- 历史最高 19.00
- 量 比 0.57
- 振 幅 4.02%
- 历史最低 0.8332
- 每 手 1
- 风险率 1.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 30, 2025 – Pyxis Oncology granted stock options to purchase 246,238 shares to four new employees under its 2022 Inducement Plan. The options have a $1.10 exercise price, with 181,238 shares vesting over four years and 65,000 shares vesting by December 31, 2025. Pyxis Oncology is a clinical-stage company developing innovative treatments for difficult cancers, focusing on its lead candidate, micvotabart pelidotin (MICVO), currently in ...
06-30 20:30
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 price target.
05-19 18:55
美股大行评级 | Compass Point：上调Affirm Holdings评级至"买入"，目标价从61美元升至64美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1109399410911752193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Femasys Inc Ordinary Shares(FEMY)"买入"评级，目标价从12美元升至15美元</p> <p>• HC Wainwright & C
03-20 09:49
Pyxis Oncology Advances Cancer Therapeutics with MICVO
Pyxis Oncology, Inc. ( ($PYXS) ) has released its Q4 earnings. Here is a breakd...
03-19 11:55
Pyxis Oncology Announces CMO Resignation and New Trials
The latest announcement is out from Pyxis Oncology ( ($PYXS) ). On March 18, 20...
03-18 20:15
Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.09) by 21.1 percent. This is a 28.65 percent increase over losses of $(1.85) per share from
03-18 19:33
Top-rated biotechs with negative enterprise values
After four consecutive years of underperformance, biotech stocks are among the most unloved segments in the market. Major industry benchmarks SPDR S&P Biotech ETF (NYSEARCA:XBI) and the iShares Biotec...
03-02 03:28
Pyxis Oncology rises on FDA fast track tag for lead asset
Shares of Pyxis Oncology (NASDAQ:PYXS) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at head and ...
02-26 20:55
美股大行评级 | 潜在升幅247%，Innoviz获机构上调目标价至4美元
<span> <meta content="no-referrer" name="referrer"></span><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Rosenblatt：上调Innoviz Technologies(INVZ)评级至"买入"，目标价从3.25美元升至4美元</p> <p>• B. Riley证券：上调Cognition Therapeutics(CGTX)评级至"买入"，目标价从1美元升至1.5美元</p> <p>• 富国银行：维持Ultragenyx制药(RARE)"超配"评级，目标价从75美元升至88美元</p> <p>• Maxim Group：首予Tru
2024-12-23 09:29
